Charting differences between tumors and normal tissue is a mainstay of cancer research.
However, clonal tumor expansion from complex normal tissue architectures potentially …

Introduction: The majority of patients with CLL will suffer from infections during their disease,
accounting for approximately 60% of deaths in CLL. Patients are predisposed to infection …

Deregulated transcriptional control caused by aberrant DNA methylation and/or histone
modifications is a hallmark of cancer cells. In chronic lymphocytic leukemia (CLL), the most …

How the genomic features of a patient's cancer relate to individual disease kinetics remains
poorly understood. Here we used the indolent growth dynamics of chronic lymphocytic …

Chronic lymphocytic leukemia (CLL) is characterized by the clonal expansion of small
mature-looking CD19+ CD23+ CD5+ B-cells that accumulate in the blood, bone marrow …

Chronic lymphocytic leukemia (CLL) with unmutated (U-CLL) or mutated (M-CLL)
immunoglobulin gene heavy-chain variable region (IGHV) displays different states of …

BIRC3 is monoallelically deleted in up to 80% of chronic lymphocytic leukemia (CLL) cases
harboring del (11q). In addition, truncating mutations in the remaining allele of this gene can …

Chronic lymphocytic leukemia has a highly variable disease course across patients, thought
to be driven by the vast inter-and intrapatient molecular heterogeneity described in several …

Alterations in global DNA methylation patterns are a major hallmark of cancer and represent
attractive biomarkers for personalized risk stratification. Chronic lymphocytic leukemia (CLL) …

The rapid progress in next-generation sequencing technologies has significantly contributed
to our knowledge of the genetic events associated with the development, progression and …